To include your compound in the COVID-19 Resource Center, submit it here.

Third Rock's Lotus position

Third Rock plans fast track for Lotus, a series A Orphan disease play

Third Rock Ventures is hoping to get from bench to proof of concept in a little more than three years with protein replacement company Lotus Tissue Repair Inc.

The firm was the sole investor in last week's tranched $26 million series A round.

Lotus hopes

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers